<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015014</url>
  </required_header>
  <id_info>
    <org_study_id>AN3365-PK-101</org_study_id>
    <secondary_id>C3501001</secondary_id>
    <nct_id>NCT01015014</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics (PK) and Tolerability Study of a Novel Drug for Treatment of Bacterial Infections</brief_title>
  <official_title>First-in-human, Two-stage, Randomized, Placebo-controlled, Double-blind, Dose Escalation Study To Determine The Safety, Tolerability, And Pharmacokinetic Profile Of An3365 In Single And Multiple Doses In Young Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetic profile
      of an antibacterial compound for treatment of hospital acquired Gram negative infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center, randomized, placebo-controlled, double-blind study to determine the safety,
      tolerability and pharmacokinetic profile of compound in single and multiple doses in young
      healthy males.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2009</start_date>
  <completion_date type="Actual">August 31, 2010</completion_date>
  <primary_completion_date type="Actual">July 31, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical safety data from 12-lead ECG, clinical laboratory tests, urinalysis, injection site tolerability, spontaneous/elicited adverse event reporting, and vital signs (blood pressure, heart rate, respiratory rate)</measure>
    <time_frame>Multiple time points up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameters to achieve appropriate exposure and estimate the dose proportionality</measure>
    <time_frame>Multiple time points up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Gram-negative Bacterial Infection</condition>
  <arm_group>
    <arm_group_label>AN3365</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AN3365</intervention_name>
    <description>LP, 600 mg vial; reconstituted in Normal Saline</description>
    <arm_group_label>AN3365</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% sodium chloride for injection</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Young healthy males, 18-45 years (inclusive) of age

          -  Healthy as judged by a responsible physician with no clinically significant
             abnormality

          -  Surgically sterile OR agrees to abstain from sexual intercourse with a female partner
             OR agrees to use a condom and spermicide during sexual intercourse with a female
             partner who uses another form of contraception

          -  Body weight above 50 kg (Body Mass Index between 19 and 30 kg/m2)

          -  Non-smokers

          -  Willing and able to comply with study instructions and commit to all follow-up visits

          -  Ability to understand, agree to and sign the study Informed Consent Form (ICF)

        Exclusion Criteria:

          -  History of serious adverse reactions or hypersensitivity to any drug; or who have a
             known allergy to any of the test product(s) or any components in the test product(s);
             or history of hypersensitivity or allergic reactions to any of the study preparations
             as described in the Investigator's Brochure

          -  Any clinically significant central nervous system, cardiac, pulmonary, metabolic,
             renal, hepatic or gastrointestinal conditions

          -  Abnormal physical findings of clinical significance at the screening examination or
             baseline

          -  History of orthostatic hypotension

          -  Clinically significant abnormal laboratory values

          -  Presence or history of allergies requiring acute or chronic treatment

          -  12 lead ECG abnormalities

          -  Major surgical interventions within 6 months of the study

          -  Has a positive pre-study Hepatitis B surface antigen; positive hepatitis C (HCV)
             antibody or detectable HCV ribonucleic acid (RNA); or positive HIV antibody result

          -  Use of prescription or non-prescription drugs

          -  Has a history of regular alcohol consumption

          -  Loss of 500 mL blood or more during the 3 month period before the study

          -  People that follow vegetarian or vegan diet

          -  Symptoms of a significant somatic or mental illness in the four week period preceding
             drug administration

          -  History of drug abuse or dependence within 12 months of the study

          -  The subject has a positive pre-study alcohol or urine drug screen

          -  Concurrent participation in another drug or device research study or within 60 days of
             post participation in another drug or device study

          -  Considered by the Investigator to be unsuitable candidate for this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lee Zane, MD, MAS</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2009</study_first_submitted>
  <study_first_submitted_qc>November 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2009</study_first_posted>
  <last_update_submitted>March 17, 2018</last_update_submitted>
  <last_update_submitted_qc>March 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gram negative</keyword>
  <keyword>bacteria</keyword>
  <keyword>infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

